DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zdcqct/ib1001) has announced the addition of the "IB1001 (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood.
However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
IB1001 is a recombinant FIX molecule that was developed by Inspiration Biopharmaceuticals and sold to Cangene in February 2013, as a result of Inspiration's bankruptcy proceedings (Cangene, Press Release, February 20, 2013). At the time of the transfer of full worldwide development and marketing rights for IB1001 to Cangene, Inspiration's marketing authorization applications were under review with the FDA and EMA.
- Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on IB1001 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for IB1001 for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China.
Key Topics Covered:
Opportunity and Unmet Need
IB1001 (trenacog alfa)
List of Tables
List of Figures
For more information visit http://www.researchandmarkets.com/research/zdcqct/ib1001
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.